{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:06:12Z","timestamp":1791237972618,"version":"4.1.0"},"reference-count":40,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s290309","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T01:39:30Z","timestamp":1624930770000},"page":"247-253","source":"Crossref","is-referenced-by-count":31,"title":["Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Francesco","family":"Bellinato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":true,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-0493","authenticated-orcid":true,"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/14728214.2020.1745773","volume":"25","author":"Balogh","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.13013","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/exd.13182","volume":"26","author":"Bertelsen","year":"2017","journal-title":"Exp Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet."},{"key":"ref11","first-page":"23","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref13","unstructured":"Reichert J. Anti-IL17 netakimab registered in Russia antibodysociety.org: antibody Society; 2019. Available from: https:\/\/www.antibodysociety.org\/antibody-therapeutic\/anti-il17-netakimab-registered-in-russia. Accessed June 15, 2021."},{"key":"ref14","unstructured":"BIOCAD registered the first Russian original therapeutic monoclonal antibody: BIOCAD biotechnology company; 2019. Available from: https:\/\/biocadglobal.com\/post\/Russian_original_therapeutic_monoclonal_antibody. Accessed December 29, 2019."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.25208\/0042-4609-2019-95-2-15-28","volume":"95","author":"Kubanov","year":"2019","journal-title":"Vestnik Dermatologii Ivenerologii"},{"key":"ref16","first-page":"56","volume":"95","author":"Bakulev","year":"2019","journal-title":"Vestnik Dermatologii Ivenerologii"},{"key":"ref17","author":"Bakulev"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.47360\/1995-4484-2020-480-488","volume":"58","author":"Korotaeva","year":"2020","journal-title":"Nauchcno-Practicheskaya Revmatologia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref20","unstructured":"ClinicalTrials.gov [Internet]. 2000 Feb 29 - Identifier NCT03482011, A study to evaluate the efficacy and safety of mirikizumab (LY3074828) in participants with moderate-to-severe plaque psoriasis (OASIS-1). Bethesda (MD): National Library of Medicine (US); 2006. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03482011?term=OASIS-1+mirikizumab&draw=2&rank=1. Accessed April 26, 2020."},{"key":"ref21","unstructured":"ClinicalTrials.gov [Internet]. 2000 Feb 29 - Identifier NCT03535194, a study to assess if mirikizumab is effective and safe compared to secukinumab and placebo in moderate to severe plaque psoriasis (OASIS-2). Bethesda (MD): National Library of Medicine (US); 2006. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03535194?term=mirikizumab&draw=2&rank=12. Accessed April 26, 2020."},{"key":"ref22","unstructured":"ClinicalTrials.gov [Internet]. 2000 Feb 29 - Identifier NCT03556202, A long-term study to evaluate safety and maintenance of treatment effect of LY3074828 in participants with moderate-to-severe plaque psoriasis (OASIS-3). Bethesda (MD): National Library of Medicine (US); 2006. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03556202?term=mirikizumab&draw=2&rank=21. Accessed April 26, 2020."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e13800","DOI":"10.1111\/dth.13800","volume":"33","author":"Salimi","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"ref27","first-page":"2310970","volume":"eCollection","author":"Cohen","year":"2018","journal-title":"J Immunol Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","volume":"3","author":"David","year":"2012","journal-title":"J Eur Acad Dermatol Veneredol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000350008","volume":"44","author":"Mattei","year":"2013","journal-title":"Curr Probl Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","volume":"11","author":"Gisondi","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"Gisondi","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref32","first-page":"4","volume":"19","author":"Sbidian","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"ref34","unstructured":"Vitae Pharmaceuticals Inc. Vitae Pharmaceuticals achieves proof-of-concept with first-in-class RORyt inhibitor in moderate to severe psoriasis. Available at: https:\/\/www.globenewswire.com\/news-release\/2016\/03\/16\/820582\/0\/en\/Vitae-Pharmaceuticals-Achieves-Proof-of-Concept-with-First-in-Class-RORyt-Inhibitor-in-Moderate-to-Severe-Psoriasis.html. Accessed March 16, 2016."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543776.2017.1262350","volume":"27(1)","author":"Gege","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1016\/j.bmcl.2018.07.044","volume":"28","author":"Bell","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PPA.S121838","volume":"11","author":"Eliasson","year":"2017","journal-title":"Patient Prefer Adher"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/1744666X.2020.1771182","volume":"16","author":"Gisondi","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1080\/09546634.2019.1610553","volume":"31","author":"Barker","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ad.2020.03.008","volume":"11","author":"Puig","year":"2020","journal-title":"Actas Dermosifiliogr"}],"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=71150","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T01:39:44Z","timestamp":1624930784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/latest-advances-for-the-treatment-of-chronic-plaque-psoriasis-with-bio-peer-reviewed-fulltext-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":40,"URL":"https:\/\/doi.org\/10.2147\/btt.s290309","relation":{},"ISSN":["1177-5491"],"issn-type":[{"value":"1177-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}